Tumour-based DNA methylation markers of breast cancer survival: A pooled analysis of 2,157 cases

Background Tumour DNA methylation is a potentially valuable marker of breast cancer survival, but previous studies have been limited by relatively small sample sizes. This study aimed to use a large sample size to identify survival-associated DNA methylation markers and develop a methylation-based signature predictive of breast cancer survival. Methods We used DNA methylation data from 2,157 breast tumours collected in the Melbourne Collaborative Cohort Study (MCCS) and nine publicly available datasets. An epigenome-wide association study (EWAS) was conducted for five-year overall survival (N = 1,992 cases). Subgroup analyses were carried out by estrogen receptor status. Pathway enrichment analyses were conducted to identify related biological pathways. Elastic net Cox regression was used to develop a signature of survival from DNA methylation data and clinical characteristics, trained on publicly available datasets and tested in the MCCS (N = 425) in addition to the main clinical characteristics. A set of triple-negative tumours (N = 165) with disease-free survival as the outcome was used for additional replication. Results We identified 2,535 CpGs showing an association (P < 1x10 ^− 7 ) with survival in age-adjusted models, including 281 after adjustment for estrogen receptor (ER) status. In ER-positive tumours, there were 389 associations, of which 315 were absent from the primary EWAS. A 228-CpG signature showed a strong association with survival in the MCCS after adjustment for clinical characteristics: per SD, HR = 1.6, 95%CI: 1.2–2.1, P = 0.001, with a C-index of 0.79, compared with a C-index of 0.75 without methylation information (C-index increase: 0.04, 95%CI: 0.01–0.10). The signature was also predictive of disease-free survival beyond clinical characteristics in triple-negative tumours (HR per SD = 1.4, 95% CI: 1.1–1.8). Conclusion Our findings revealed numerous CpG sites where tumour DNA methylation was associated with breast cancer survival, and potential prognostic signals specific to ER-positive tumours. A substantial improvement in predicting five-year survival was achieved by adding a 228-CpG epigenetic score to clinical characteristics alone. These results highlight the value of DNA methylation markers for the prediction of breast cancer outcomes.